



## IBA Signs Second Proteus<sup>®</sup>ONE Contract in Japan

**Contract to install next generation compact proton therapy system making proton therapy more accessible worldwide**

Louvain-la-Neuve, Belgium, June 10<sup>th</sup>, 2014 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has signed a second contract with a significant upfront payment for the installation of its compact single-room proton therapy system Proteus<sup>®</sup>ONE\* in Japan, subject to obtaining market authorization. Final price and identity of the contractor is not disclosed. The typical end-user price for Proteus<sup>®</sup>ONE is between EUR 20 and 25 million, depending on exact scope of supply. The center, which will be installed on the Hokkaido island in the North of Japan, is expected to treat its first patient in 2017.

**Olivier Legrain, Chief Executive Officer of IBA commented:** *"This second Proteus<sup>®</sup>ONE order in the demanding and sophisticated Japanese proton therapy market, further demonstrates the success of our compact proton therapy system. The momentum being created by IBA's next generation proton therapy solutions such as Proteus<sup>®</sup>ONE and Pencil Beam Scanning is further enhancing the adoption of this cutting-edge therapy and ensuring our continued dominance of the international market."*

Today, more than half of all proton therapy clinical facilities worldwide are equipped with IBA systems. This includes 17 proton therapy centers currently in operation and 11 additional centers under development of which five Proteus<sup>®</sup>ONE. Over 25,000 patients have been treated using IBA equipment, which is more than all major competitive installations combined.

Proteus<sup>®</sup>ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus<sup>®</sup>ONE is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. Proteus<sup>®</sup>ONE makes Proton Therapy easy.

*\* Proteus<sup>®</sup>ONE is the brand name of a new configuration of the Proteus<sup>®</sup> 235, including some new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing*

- ENDS -



## Notes to Editors

### About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life.

### About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing about 1000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

### For further information please contact:

#### IBA

Jean-Marc Bothy  
Chief Financial Officer  
+32 10 475 890  
[Investorrelations@iba-group.com](mailto:Investorrelations@iba-group.com)

Thomas Ralet  
Vice-President Corporate Communication  
+32 10 475 890  
[thomas.ralet@iba-group.com](mailto:thomas.ralet@iba-group.com)

### For media and investor enquiries:

#### Consilium Strategic Communications

Amber Bielecka, Mary-Jane Elliott, Matthew  
Neal, Jessica Hodgson, Ivar Milligan  
+44 (0) 20 3709 5700  
[IBA@consilium-comms.com](mailto:IBA@consilium-comms.com)